Fresenius Kabi officially opened the new laboratory and office areas at its Innovation & Development Center in Graz, Austria, at the end of May. Around 40 colleagues from analytics and formulation development now share a joint rental building in Grambach, close to Graz. The different departments have been moved closer together, fostering collaboration and communication.
Dr. Michael Schönhofen, President Pharmaceuticals Division, said: "Our Innovation & Development employees here in Graz make an important contribution in the development of new generics. These drugs are extremely important in providing affordable therapies for patients worldwide. Our employees deserve the best-possible working environment."
About 70 colleagues develop generics at the Fresenius Kabi Innovation & Development Center in Graz. The healthcare company also employs about 900 additional employees at its production site in Graz where it produces I.V. drugs for the national and international markets.